Dr. Tien-I Karleen Su, MD
Claim this profileMedvin Clinical Research
Studies Arthritis
Studies Rheumatoid Arthritis
2 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Tien-I Karleen Su, MD is currently running
Splenic Stimulation
for Rheumatoid Arthritis
This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have active rheumatoid arthritis (RA) and have an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). A sufficient number of participants will be enrolled so that approximately 28 participants will undergo device implantation.
Recruiting2 awards N/A3 criteria
Vagus Nerve Stimulation
for Rheumatoid Arthritis
The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll 250 subjects at 40 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 180-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.
Recruiting1 award Phase 34 criteria
More about Tien-I Karleen Su, MD
Clinical Trial Related2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Tien-I Karleen Su, MD has experience with
- SetPoint System
- Baricitinib
- Galvani System
Breakdown of trials Tien-I Karleen Su, MD has run
Arthritis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tien-I Karleen Su, MD specialize in?
Tien-I Karleen Su, MD focuses on Arthritis and Rheumatoid Arthritis. In particular, much of their work with Arthritis has involved treating patients, or patients who are undergoing treatment.
Is Tien-I Karleen Su, MD currently recruiting for clinical trials?
Yes, Tien-I Karleen Su, MD is currently recruiting for 2 clinical trials in Whittier California. If you're interested in participating, you should apply.
Are there any treatments that Tien-I Karleen Su, MD has studied deeply?
Yes, Tien-I Karleen Su, MD has studied treatments such as SetPoint System, Baricitinib, Galvani System.
What is the best way to schedule an appointment with Tien-I Karleen Su, MD?
Apply for one of the trials that Tien-I Karleen Su, MD is conducting.
What is the office address of Tien-I Karleen Su, MD?
The office of Tien-I Karleen Su, MD is located at: Medvin Clinical Research, Whittier, California 90602 United States. This is the address for their practice at the Medvin Clinical Research.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.